Skip to main content
Symptom
dx.
Menu
Clinical Reference
Approaches
I have a symptom
Management
I know the diagnosis
Orthopedic Injuries
Fractures & dislocations
Calculators
Clinical calculators
Practical Skills
ECG
Interpretation guide
POCUS
Bedside ultrasound
Procedures
Step-by-step guides
Resuscitation
ACLS / PALS / NRP
Learn
Blog
Articles & updates
Deep Dive
In-depth clinical reviews
About
Our mission
Symptom
dx.
Clinical Reference
Approaches
I have a symptom
Management
I know the diagnosis
Orthopedic Injuries
Fractures & dislocations
Calculators
Clinical calculators
Practical Skills
ECG
Interpretation guide
POCUS
Bedside ultrasound
Procedures
Step-by-step guides
Resuscitation
ACLS / PALS / NRP
Learn
Blog
Articles & updates
Deep Dive
In-depth clinical reviews
About
Our mission
Get Started
Menu
Clinical Reference
Approaches
I have a symptom
Management
I know the diagnosis
Orthopedic Injuries
Fractures & dislocations
Calculators
Clinical calculators
Practical Skills
ECG
Interpretation guide
POCUS
Bedside ultrasound
Procedures
Step-by-step guides
Resuscitation
ACLS / PALS / NRP
Learn
Blog
Articles & updates
Deep Dive
In-depth clinical reviews
About
Our mission
Loading...
Bullous Pemphigoid
Cardiovascular Presentations
Abdominal aortic aneurysm
Acute coronary syndrome (NSTEMI)
Acute coronary syndrome (STEMI)
Acute decompensated heart failure
Acute limb ischemia
Acute mesenteric ischemia
Aortic dissection
Aortic stenosis
Atrial fibrillation and flutter
Bradyarrhythmia and heart block
Cardiac arrest
Deep vein thrombosis
Myocarditis
Pericarditis
Pulmonary embolism
Stable angina
Superficial thrombophlebitis
Superior vena cava syndrome
Supraventricular tachycardia
Syncope (cardiogenic)
Unstable angina
Ventricular tachycardia
Respiratory Presentations
Acute bronchitis
Acute respiratory failure
Aspiration pneumonia
Asthma exacerbation
Bronchiolitis
Community-acquired pneumonia
COVID-19 pneumonia
COPD exacerbation
Croup
Croup (laryngotracheobronchitis)
Epiglottitis
Hemothorax
Hospital-acquired pneumonia
Pleural effusion
Pneumothorax (traumatic)
Pulmonary contusion
Spontaneous pneumothorax
Neurological Presentations
Bell's palsy
Benign paroxysmal positional vertigo
Brain abscess
Cauda equina syndrome
Cervical radiculopathy
Concussion (mild traumatic brain injury)
Encephalitis
Guillain-Barré syndrome
Hemorrhagic stroke (intracerebral)
Ischemic stroke
Lumbar radiculopathy
Malignant spinal cord compression
Migraine
Peripheral neuropathy (acute)
Retropharyngeal abscess
Schizophrenia (acute exacerbation)
Seizure (breakthrough:known epilepsy)
Seizure (first-time)
Spinal cord injury
Status epilepticus
Subarachnoid hemorrhage
Tension headache
Transient ischemic attack
Traumatic brain injury (moderate-severe)
Vestibular neuritis
Viral meningitis
Gastrointestinal Presentations
Acute appendicitis
Acute cholecystitis
Acute diverticulitis
Acute pancreatitis
Anal fissure
Choledocholithiasis and cholangitis
Clostridioides difficile colitis
Gastritis
Gastroenteritis (viral and bacterial)
Gastroesophageal reflux disease
Incarcerated or strangulated hernia
Inflammatory bowel disease flare
Large bowel obstruction
Lower GI hemorrhage
Peptic ulcer disease
Perforated viscus
Small bowel obstruction
Upper GI hemorrhage
Genitourinary and Reproductive Presentations
Acute prostatitis
Acute urinary retention
Ectopic pregnancy
Epididymitis
Orchitis
Ovarian torsion
Paraphimosis
Pelvic inflammatory disease
Priapism
Pyelonephritis
Renal laceration
Ruptured ovarian cyst
Testicular torsion
Tubo-ovarian abscess
Urinary tract infection (uncomplicated)
Urolithiasis (renal colic)
Vaginal bleeding (non-pregnant)
Infectious Disease Presentations
Acute sinusitis
Acute tonsillitis
Acute upper respiratory infection
Animal bite
Bacterial meningitis
Cellulitis
Conjunctivitis (bacterial)
Dental abscess
Endocarditis
Febrile neutropenia
Fournier gangrene
Hand-foot-mouth disease
Hepatitis (acute)
Herpes zoster
HIV-related illness
Human bite
Impetigo
Infected diabetic foot ulcer
Infectious mononucleosis
Influenza
Necrotizing fasciitis
Osteomyelitis
Otitis externa
Parasitic infection
Periorbital cellulitis
Peritonsillar abscess
Scabies
Sepsis
Septic arthritis
Spontaneous bacterial peritonitis
Tick-borne illness (Lyme disease)
Tinea infection
Tuberculosis
Viral exanthem
Wound infection
Trauma Presentations
Achilles tendon rupture
ACL and mceniscus tear
Ankle fracture
Ankle sprain
Burn
Calcaneus fracture
Cervical spine fracture
Clavicle fracture
Dental avulsion
Distal radius fracture
Drowning
Elbow fracture and dislocation
Electrical injury
Facial bone fracture
Facial laceration
Femur fracture
Fingertip amputation
Forearm fracture (radius and ulna)
Frostbite
Hand:finger laceration
Heat exhaustion
Heat stroke
Hip fracture
Humeral shaft fracture
Knee dislocation
Knee sprain
Lightning injury
Mandible fracture
Metacarpal fracture
Metatarsal fracture
Muscle strain
Nasal fracture
Non-accidental trauma
Orbital fracture
Patella fracture
Phalanx fracture (finger)
Proximal humerus fracture
Pulmonary contusion
Rib fracture
Rotator cuff tear (acute traumatic)
Scalp laceration
Scaphoid fracture
Shoulder dislocation
Skull fracture
Splenic laceration
Sternal fracture
Supracondylar pediatric fracture
Tendon laceration (hand:wrist)
Thoracic and lumbar spine fracture
Tibia:fibula fracture
Tibial plateau fracture
Toe fracture
Traumatic epistaxis
Traumatic hyphema
Toxicologic Presentations
Acetaminophen toxicity
Alcohol intoxication
Alcohol withdrawal
Anticholinergic toxicity
Anticoagulant overdose
Benzodiazepine overdose
Benzodiazepine:sedative overdose
Beta-blocker and calcium channel blocker toxicity
Carbon monoxide poisoning
Caustic ingestion
Digoxin toxicity
Drug eruption
Foreign body ingestion
Opioid intoxication
Opioid overdose
Opioid withdrawal
Organophosphate
Salicylate toxicity
Serotonin syndrome
Stimulant intoxication (cocaine, methamphetamine)
Tricyclic antidepressant overdose
Psychiatric Presentations
Acute anxiety
Acute psychosis
Agitation:behavioral emergency
Bipolar disorder
Conversion disorder
Major depressive episode
Neuroleptic malignant syndrome
Suicidal ideation and attempt
Musculoskeletal and Rheumatologic Presentations
Acute low back pain (mechanical)
Bursitis
Cervical radiculopathy
Costochondritis
Gout (acute)
Lumbar radiculopathy
Pseudogout
Tendinitis
Dermatology Presentations
Acute eczema (Eczema acute flare)
Allergic contact dermatitis
Erythema multiforme
Henoch-Schönlein purpura
Pressure injury
Psoriasis (acute flare)
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Urticaria (acute)
Environmental and Exposure Presentations
Envenomation (snake, spider, insect)
High-altitude illness
Hypothermia
Hematologic and Oncologic Presentations
Acute chest syndrome
Coagulopathy
Hyperviscosity syndrome
Sickle cell crisis (vaso-occlusive)
Symptomatic anemia
Thrombocytopenia (severe)
Tumor lysis syndrome
Pediatric-Specific Presentations
Bronchiolitis
Croup
Emergency delivery
Febrile seizure
Kawasaki disease
Neonatal jaundice
Neonatal sepsis
Nursemaid's elbow
Pediatric fever 0 to 28 days
Pediatric fever 29 to 60 days
Pediatric fever 61 to 90 days
Pyloric stenosis
Slipped capital femoral epiphysis
Intussusception
Endocrine and Metabolic Presentations
Adrenal crisis
Diabetic ketoacidosis
Hypercalcemia
Hyperosmolar hyperglycemic state
Hypertensive emergency
Hypertensive urgency
Hypoglycemia
Myasthenia gravis crisis
Myxedema coma
Severe hyperkalemia
Severe hyponatremia
Thyroid storm
ENT and Maxillofacial Presentations
Acute laryngitis
Acute otitis media
Acute pharyngitis
Cerumen impaction
Epistaxis (anterior)
Nasal foreign body
Otitis externa
Tympanic membrane perforation
Ophthalmologic Presentations
Acute angle-closure glaucoma
Central retinal artery occlusion
Chemical eye injury
Corneal abrasion
Corneal ulcer
Globe rupture
Ocular foreign body
Orbital cellulitis
Retinal detachment
Obstetric Presentations
Hyperemesis gravidarum
Painful vaginal bleeding in pregnancy
Placenta previa
Placental abruption
Preeclampsia:eclampsia
Preterm labor
Threatened:inevitable:incomplete abortion
Systemic and Miscellaneous Presentations
Anaphylaxis
Angioedema
Cannabis-induced hyperemesis
Bullous Pemphigoid
POCUS
Procedures
Calculators
Resuscitation
ECG Guide
Back
Clinical Assessment Checklist
Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Life-threatening presentations requiring urgent action
▶
Extensive skin loss with systemic infection signs
▶
Fever, tachycardia, hypotension suggesting sepsis
Sepsis is the leading cause of death in bullous pemphigoid
Hemodynamic instability from secondary infection
▶
SBP < 90 mmHg or MAP < 65 mmHg
Initiate sepsis bundle: IV fluids, blood cultures, broad-spectrum antibiotics within 1 hour
Airway compromise from extensive oropharyngeal involvement
▶
Rare but can occur with severe mucosal disease
Escalate to critical care if oropharyngeal edema or stridor
Monitoring and targets
Monitoring priorities in severe or hospitalized BP
▶
Blister count trend
▶
>10 new blisters per day defines extensive disease
Track daily to gauge treatment response
Infection surveillance
▶
Daily wound assessment for erythema, purulence, odor
Temperature and white cell count trend
Treatment toxicity monitoring
▶
Blood glucose twice daily on systemic corticosteroids
Blood pressure monitoring
Electrolytes every 48 to 72 hours if hypokalemia risk
Escalation triggers and consults
Escalation and consultation indications
▶
Dermatology — all confirmed or suspected cases
▶
Skin biopsy and direct immunofluorescence required for definitive diagnosis
Urgent if diagnosis uncertain or disease rapidly progressive
Infectious disease if secondary wound infection with systemic sepsis
▶
Wound culture and antibiogram to guide antibiotic selection
Consider MRSA coverage in healthcare-associated infections
Ophthalmology if any ocular symptoms
▶
Rule out ocular mucous membrane pemphigoid (risk of scarring, blindness)
ICU if septic shock or hemodynamic instability unresponsive to initial resuscitation
History
Symptom onset and character
Pruritus as the cardinal early symptom
▶
Often precedes blisters by weeks to months
Severe, intractable pruritus even before visible blisters
Nonbullous prodromal phase occurs in more than 20% of patients
Blister characterization
▶
Tense dome-shaped bullae on erythematous or normal skin
Arising on flexural surfaces, trunk, groin, inner thighs
New blister count per day for severity grading
▶
Fewer than 10 new blisters per day: moderate disease
More than 10 new blisters per day: extensive disease
Medication history
Drug triggers requiring review and potential discontinuation
▶
DPP-4 inhibitors (gliptins): strongest evidence
▶
Vildagliptin, linagliptin, sitagliptin — odds ratio approximately 2 to 4
HLA-DQA1*05 allele associated with DPP-4 inhibitor-induced BP
Immune checkpoint inhibitors
▶
PD-1 and PD-L1 inhibitors: nivolumab, pembrolizumab
Usually occurs weeks to months after initiation
Loop diuretics and aldosterone antagonists
▶
Furosemide, spironolactone — reported associations
Neuroleptics and antipsychotics
Penicillins and derivatives
Risk factors
Demographic and comorbid risk factors
▶
Age >70 years: strongest demographic risk factor
▶
Incidence rises sharply after age 70
Institutionalized elderly at highest risk
Neurological diseases
▶
Dementia: odds ratio approximately 4 to 5
Parkinson disease: odds ratio approximately 3
Stroke: odds ratio approximately 2.7
Epilepsy, multiple sclerosis also associated
Diabetes mellitus (partly mediated by DPP-4 inhibitor use)
Immobility and poor functional status
▶
Low Karnofsky performance score predicts worse outcomes
Psoriasis: independent association reported
Associated symptoms and review of systems
Mucosal involvement assessment
▶
Oral mucosal blistering or erosions present in fewer than 30% of BP
Conjunctival injection, eye pain, or visual change — rule out ocular mucous membrane pemphigoid
Genital erosions
Neurological symptom review
▶
Cognitive decline, tremor, gait disturbance, seizure history
BP strongly associated with neurological disease — may be presenting comorbidity
Systemic review
▶
Fever, chills, purulent wound discharge suggesting superinfection
Dyspnea or chest pain — pneumonia risk 3 times higher than age-matched controls
Polyuria, polydipsia if on corticosteroids (steroid-induced diabetes)
Collateral history
Caregiver and medication reconciliation
▶
Many BP patients have dementia and cannot reliably report timeline
Pharmacy records for recent DPP-4 inhibitor or checkpoint inhibitor initiation
Social history: functional status, caregiver availability, ability to apply topical medications
Prior episodes of unexplained pruritus or blistering
Physical Exam
Skin examination
Blister morphology and distribution
▶
Tense dome-shaped bullae 1 to 3 cm on erythematous or normal skin
Flexural predilection: inner thighs, axillae, groins, abdomen
Generalized distribution in severe disease
Urticarial plaques, eczematous patches, excoriations in prodromal phase
Nikolsky sign
▶
Negative in bullous pemphigoid
Positive Nikolsky sign suggests pemphigus vulgaris instead
Erosions and complications
▶
Erosions with serous or hemorrhagic crusting at sites of ruptured bullae
Signs of secondary infection: erythema, warmth, purulence, malodor
No scarring or milia (distinguishes BP from epidermolysis bullosa acquisita and cicatricial pemphigoid)
Mucosal examination
Oral and conjunctival assessment
▶
Oral mucosa: blistering, erosions, white plaques
Conjunctival injection, symblepharon, or scarring (ocular mucous membrane pemphigoid risk)
Genital mucosa involvement
Mucosal predominance should shift differential toward mucous membrane pemphigoid
Vitals and general assessment
Severity and systemic involvement markers
▶
Temperature: fever suggests secondary infection or sepsis
Heart rate and blood pressure: hemodynamic compromise with extensive disease or sepsis
Blister count documentation: fewer than or more than 10 new blisters per day
Overall body surface area involvement estimate
PITFALLS
Common diagnostic errors
▶
Nonbullous prodromal phase misdiagnosed as eczema, urticaria, or scabies
▶
Diagnosis delay of months is common without high index of suspicion
Tense blisters are the distinguishing feature once they appear
Nikolsky sign not tested — failure to distinguish from pemphigus vulgaris
▶
Pemphigus has flaccid blisters, mucosal predominance, and positive Nikolsky
Mucosal involvement underestimated
▶
Ocular involvement requires urgent ophthalmology referral to prevent scarring
Differential Diagnosis
Autoimmune blistering diseases
Primary differentials within pemphigoid group
▶
Pemphigus vulgaris (ICD-10 L10.0)
▶
Flaccid blisters, positive Nikolsky sign
Mucosal predominance (often oral first presentation)
Intraepidermal acantholysis on histology
Anti-desmoglein 1 and 3 antibodies
Mucous membrane pemphigoid (ICD-10 L12.1)
▶
Mucosal predominance with scarring
Ocular, oral, genital, laryngeal involvement
Risk of blindness from conjunctival scarring
Epidermolysis bullosa acquisita (ICD-10 Q81.9)
▶
Acral and mechanically induced blisters
Scarring and milia formation
Dermal-side IgG binding on salt-split skin (versus epidermal side in BP)
Linear IgA bullous dermatosis (ICD-10 L13.8)
▶
String of pearls blister pattern
IgA deposits on direct immunofluorescence
Often drug-induced (vancomycin most common trigger)
Other blistering conditions
Inflammatory and infectious mimics
▶
Dermatitis herpetiformis (ICD-10 L13.0)
▶
Grouped vesicles on extensor surfaces
Granular IgA in dermal papillae
Celiac disease association
Scabies with secondary bullae
▶
Common misdiagnosis in institutionalized elderly
Burrows, interdigital distribution, contact history
Contact dermatitis and eczema
▶
Most common misdiagnosis in nonbullous prodromal phase
No autoantibodies, responds to topical steroids differently
Stevens-Johnson syndrome and toxic epidermal necrolysis
▶
Acute onset, mucosal involvement, systemic toxicity
Positive Nikolsky sign, epidermal detachment
Bullous diabeticorum
▶
Spontaneous blisters on extremities in diabetics
No autoantibodies, self-limited
Laboratory Tests
Serologic diagnostic tests
Anti-BP180 NC16A ELISA
▶
Pooled sensitivity approximately 82%, specificity approximately 94%
Most clinically useful serologic test for diagnosis
Levels correlate with disease activity and relapse risk
High levels at planned treatment discontinuation predict relapse
Anti-BP230 ELISA
▶
Lower sensitivity approximately 59%, specificity approximately 95%
Best used as adjunctive or confirmatory test
Combined BP180 plus BP230 ELISA sensitivity reaches approximately 90%
Total serum IgE
▶
Frequently elevated in BP
Not diagnostic alone but supports clinical picture
Baseline and monitoring labs
Pre-treatment baseline panel
▶
Complete blood count
▶
Peripheral eosinophilia common and supportive of diagnosis
Leukocytosis if secondary infection present
Comprehensive metabolic panel
▶
Baseline glucose and HbA1c before corticosteroid initiation
Renal function affects choice of steroid-sparing agents
Hepatic panel before immunosuppressive agent initiation
TPMT enzyme activity if azathioprine is planned
▶
Deficiency predicts severe azathioprine toxicity
Required before initiating azathioprine
Infection workup
Secondary infection evaluation
▶
Wound culture and sensitivity if purulence or malodor
▶
Guides targeted antibiotic selection
MRSA coverage empirically if healthcare-associated
Blood cultures if systemic sepsis features present
▶
Prior to antibiotic initiation when feasible
CBC with differential and CRP for infection surveillance during treatment
Diagnostic Tests
Scoring Systems
Bullous Pemphigoid Disease Area Index (BPDAI)
▶
Validated severity scoring tool for BP
▶
Scores bullae, urticarial lesions, and erosions separately on skin and mucosae
Score 0 to 360 total
Used to track treatment response in clinical trials
Not widely used in emergency settings but relevant for specialist follow-up
Severity classification for treatment decisions
▶
Mild: localized disease, manageable pruritus, fewer than 10 new blisters per day
▶
Topical high-potency corticosteroids adequate
Moderate: up to 10 new blisters per day
▶
Systemic therapy or whole-body topical clobetasol considered
Extensive or severe: more than 10 new blisters per day
▶
Systemic corticosteroids or whole-body clobetasol propionate 40 g per day required
MRI
MRI role in bullous pemphigoid
▶
Not a primary diagnostic modality for BP itself
▶
No established MRI protocol for BP diagnosis
Skin biopsy and immunofluorescence are gold standard
Brain MRI indications
▶
New neurological symptoms requiring evaluation (stroke, dementia workup)
BP has strong associations with stroke (OR 2.7), dementia, Parkinson disease
Contraindications
▶
Hemodynamically unstable patient
Non-MRI-compatible implants
CT
CT imaging in BP management
▶
CT chest indications
▶
Pneumonia suspected — BP patients have 3 times higher pneumonia risk than controls
Pulmonary embolism concern given elevated cardiovascular morbidity
CT chest if CXR equivocal with high clinical suspicion
CT abdomen indications
▶
Malignancy workup if checkpoint inhibitor-induced BP
Age-appropriate cancer screening beyond standard guidelines is not routinely recommended
Contrast considerations
▶
Renal function assessment before contrast administration
Allergy history review
Ultrasound
Ultrasound applications in BP
▶
Wound and soft tissue ultrasound
▶
Deep tissue infection assessment when cellulitis or abscess suspected
Abscess localization for drainage planning
Point-of-care ultrasound for hemodynamically unstable patients
▶
Cardiac function assessment in suspected septic shock
IVC collapsibility for fluid responsiveness estimation
Limitations
▶
Operator dependent
Not a diagnostic tool for BP itself
Skin biopsy and immunofluorescence
Histopathology and immunofluorescence — gold standard
▶
Lesional skin biopsy (H&E)
▶
Subepidermal blister with eosinophilic infiltrate
Supportive but not specific for BP
Direct immunofluorescence (DIF) of perilesional skin
▶
Gold standard for diagnosis
Linear IgG and C3 deposits at the basement membrane zone
Sensitivity approximately 91%, specificity approximately 98%
Biopsy should be from normal-appearing perilesional skin, not within blister
Indirect immunofluorescence on salt-split skin
▶
Epidermal-side IgG binding confirms BP
Dermal-side binding distinguishes epidermolysis bullosa acquisita
Disposition
Admission indications
Inpatient admission criteria
▶
Extensive disease with inability to manage wound care at home
▶
More than 10 new blisters per day
Greater than 30% body surface area involvement
Secondary infection with systemic signs
▶
Fever, tachycardia, leukocytosis, hemodynamic instability
Sepsis requiring IV antibiotics
Frail elderly or patients with dementia without adequate caregiver support
▶
Cannot apply topical medications independently
Nutritional compromise from extensive skin erosions
Initiation of systemic immunosuppression requiring monitoring
▶
High-dose systemic corticosteroids in patients with significant comorbidities
Rituximab or IVIG infusion
Fluid or electrolyte imbalance from extensive skin involvement
Discharge criteria
Copy
Safe outpatient management criteria
▶
Mild to moderate disease with accessible skin involvement
▶
Fewer than 10 new blisters per day
Wound care feasible at home with caregiver or community nursing
Stable on oral treatment regimen
▶
Doxycycline 200 mg daily, topical clobetasol, or oral prednisolone
Adequate support system and functional capacity
▶
Caregiver available for topical medication application if needed
Dermatology follow-up arranged within 1 to 2 weeks for biopsy results and treatment adjustment
Transfer and specialist referral
Specialist consultation requirements
▶
Dermatology: all confirmed or suspected cases for biopsy, DIF, and ongoing management
Ophthalmology: any ocular symptoms, conjunctival injection, visual changes
Infectious disease: complicated wound infections, sepsis requiring multidrug coverage
Neurology: new neurological symptoms requiring investigation
Treatment
Wound care and supportive measures
Local wound management
▶
Gentle cleansing with mild soap or saline
▶
Daily wound care to reduce infection risk
Non-adherent dressings over erosions
Blister management technique
▶
Large tense bullae: lance with sterile technique
Leave blister roof intact to protect underlying dermis
Antihistamines for pruritus control
▶
Cetirizine 10 mg orally once daily
Hydroxyzine 25 mg orally every 6 to 8 hours (use with caution in elderly)
Topical corticosteroids
Clobetasol propionate 0.05% — first-line therapy
▶
Localized or mild disease
▶
Apply twice daily to active lesions
Taper frequency as lesions resolve
Moderate disease: whole-body clobetasol propionate
▶
10 to 30 g per day initial dose
Taper over approximately 4 months as disease controlled
Extensive or severe disease: whole-body clobetasol propionate
▶
40 g per day initial dose
Taper over approximately 12 months
Safer than equivalent systemic corticosteroid doses in elderly
Class I evidence base for efficacy in BP (Cochrane 2023)
Systemic corticosteroids
Oral prednisolone — first-line systemic option
▶
Standard dosing
▶
0.5 mg per kg per day orally
Doses above 0.75 mg per kg per day offer no additional benefit
Higher doses associated with increased mortality in elderly patients
Taper schedule
▶
Begin taper once no new blisters for 2 to 3 weeks
Slow taper over 6 to 12 months depending on disease activity
Monitor anti-BP180 levels to guide taper — elevated levels predict relapse
Corticosteroid toxicity prevention
▶
Calcium 1000 to 1500 mg per day and vitamin D 800 IU per day supplementation
Proton pump inhibitor for GI protection if high risk
Bone density monitoring if prolonged therapy
Doxycycline — preferred in frail elderly
Doxycycline 200 mg per day orally
▶
Non-inferior to prednisolone for blister control in randomized controlled trial (Williams et al. Lancet 2017)
▶
Significantly fewer serious adverse events than prednisolone
Preferred in frail elderly patients with multiple comorbidities
Mechanism: anti-inflammatory and anti-blister properties via matrix metalloproteinase inhibition
Duration: continue until blister control achieved then taper
Contraindications
▶
Avoid in pregnancy and children under 8 years
Photosensitivity counseling required
Steroid-sparing immunosuppressive agents
Azathioprine
▶
Dosing: 1 to 3 mg per kg per day orally
▶
Start at 50 mg per day and titrate based on tolerance
Requires TPMT testing before initiation
Monitoring: CBC and LFTs every 1 to 3 months
Onset of action: 4 to 8 weeks
Mycophenolate mofetil
▶
Dosing: 1000 to 1500 mg orally twice daily
▶
Alternative to azathioprine as steroid-sparing agent
Avoid in pregnancy (teratogenic)
Monitoring: CBC and renal function monthly
Methotrexate
▶
Dosing: 5 to 15 mg orally once weekly
▶
Folic acid 1 mg per day supplementation required
Monitoring: CBC, LFTs, and creatinine every 4 to 8 weeks
Dapsone
▶
Dosing: 50 to 100 mg orally once daily
▶
G6PD testing required before initiation
Risk of hemolytic anemia and methemoglobinemia
Biologics and advanced therapies
Dupilumab — FDA-approved for BP in adults
▶
Dosing: 300 mg subcutaneously every 2 weeks (after 600 mg loading dose)
▶
IL-4 and IL-13 receptor antagonist
Approved for BP in adults based on randomized controlled trial data (2023)
Consider in moderate-to-severe BP with inadequate response to conventional therapy
Generally well tolerated; injection site reactions and conjunctivitis possible
Rituximab
▶
Dosing: 1000 mg IV infusion twice, 2 weeks apart (rheumatoid arthritis protocol)
▶
Or 375 mg per m2 IV weekly for 4 weeks (lymphoma protocol)
Pre-medicate with methylprednisolone, acetaminophen, antihistamine
Used for refractory BP or as corticosteroid-sparing in high-risk patients
Infusion reaction monitoring required
Omalizumab
▶
Anti-IgE monoclonal antibody
Dosing based on IgE levels and body weight per approved dosing table
Option for refractory BP with elevated total IgE
IVIG
▶
Dosing: 2 g per kg per cycle over 2 to 5 days monthly
▶
Reserved for severe refractory cases
Pre-infusion IgA level to rule out IgA deficiency
Antibiotic therapy for secondary infection
Secondary wound infection management
▶
Mild local infection: topical antimicrobial (mupirocin) plus wound care
Moderate to severe cellulitis or sepsis
▶
Cephalexin 500 mg orally every 6 hours for mild cellulitis if outpatient
Cefazolin 1 to 2 g IV every 8 hours for moderate inpatient cellulitis
Vancomycin 15 to 20 mg per kg IV every 8 to 12 hours for MRSA coverage when indicated
▶
AUC-guided monitoring per institutional protocol
Duration guided by clinical response and culture results
Special Populations
Pregnancy
Gestational considerations for bullous pemphigoid
▶
BP rare in pregnancy; differentiate from pemphigoid gestationis
▶
Pemphigoid gestationis: pregnancy-specific, anti-BP180 antibodies, begins periumbilically
True BP in pregnancy is extremely uncommon
Medication safety in pregnancy
▶
Doxycycline contraindicated (tooth discoloration and bone growth effects in fetus)
Mycophenolate mofetil contraindicated (teratogenic — Category X)
Methotrexate contraindicated (teratogenic)
Azathioprine: relatively safer option under specialist guidance if necessary
Topical clobetasol: use with caution, limit body surface area covered
Preferred treatment approach in pregnancy
▶
Topical high-potency steroids for localized disease
Low-dose oral prednisolone for systemic therapy if required
Maternal oxygenation and nutritional status monitoring
Fetal monitoring
▶
Neonatal skin examination — maternal autoantibodies can cross placenta
Obstetric collaboration for delivery planning
Geriatric
Older adult specific considerations
▶
BP is predominantly a disease of patients over 70 years
▶
Incidence 21 to 30 per 100,000 person-years in those over 80
One-year mortality 20 to 40%, approximately 2 to 3 times higher than age-matched controls
Treatment selection priorities
▶
Prefer topical clobetasol propionate or doxycycline over systemic corticosteroids when possible
Oral prednisolone greater than 0.5 mg per kg per day associated with increased mortality in elderly
Doxycycline 200 mg per day: comparable blister control with significantly fewer serious adverse events
Corticosteroid toxicity risks in elderly
▶
Delirium and cognitive worsening — monitor mental status
Steroid-induced diabetes: glucose monitoring twice daily
GI bleeding: proton pump inhibitor prophylaxis
Osteoporotic fractures: calcium, vitamin D, bisphosphonate if prolonged therapy
Fluid retention and cardiovascular decompensation
Functional and social considerations
▶
Many patients have dementia — caregiver engagement essential for wound care
Medication reconciliation critical: DPP-4 inhibitor discontinuation may induce remission
Discharge planning must account for ability to apply topical medications
Pediatrics
Pediatric bullous pemphigoid
▶
Rare in children; differs from adult disease
▶
More common in infants under 1 year (infantile BP)
Acral distribution often predominant in infants
Facial involvement more common than in adults
Diagnostic approach in children
▶
DIF and ELISA confirm diagnosis as in adults
Consider epidermolysis bullosa in neonates before pursuing autoimmune workup
Treatment in pediatric patients
▶
Topical clobetasol propionate: first-line for localized disease
Oral prednisolone: 0.5 to 1 mg per kg per day for systemic therapy
Doxycycline: avoid in children under 8 years (dental staining)
Dapsone: 0.5 to 2 mg per kg per day in older children after G6PD testing
Prognosis in children
▶
Infantile BP often self-limited — remission within 1 to 2 years common
Better prognosis than adult disease generally
Background
Epidemiology
Incidence and prevalence
▶
Most common autoimmune subepidermal blistering disease worldwide
▶
Incidence 2.5 to 42.8 per million population per year (wide geographic variation)
Rising incidence over past decades — partly attributed to aging population and increased DPP-4 inhibitor use
Age and sex distribution
▶
Predominantly affects adults over 70 years
Incidence increases sharply after age 70
Slight male predominance in most studies
Mortality
▶
One-year mortality 20 to 40%
Mortality approximately 2 to 3 times higher than age-matched controls
Leading causes of death: secondary infection (pneumonia, sepsis), cardiovascular events
Treatment-related adverse effects contribute significantly to morbidity and mortality
Comorbidity associations
▶
Neurological diseases: dementia, Parkinson disease, stroke, epilepsy, MS — strong and consistent associations
Cardiovascular disease risk elevated
Three times higher pneumonia risk than age-matched controls
Pathophysiology
Autoimmune mechanisms
▶
Autoantibodies target hemidesmosomal proteins at the dermal-epidermal junction
▶
BP180 (type XVII collagen, BPAG2): primary pathogenic target
BP230 (dystonin, BPAG1): secondary target, cytoplasmic hemidesmosomal protein
IgG autoantibodies activate complement and recruit eosinophils and neutrophils
Tissue destruction cascade
▶
IgG binding to BP180 NC16A domain triggers complement activation
Eosinophil and mast cell degranulation releases proteases
Matrix metalloproteinases cleave the basement membrane zone
Subepidermal blister formation results from separation at lamina lucida
Role of IgE
▶
IgE anti-BP180 antibodies also present in most patients
IgE-mediated mast cell activation may contribute to pruritus severity
Rationale for omalizumab (anti-IgE) efficacy in BP
Neurological disease link pathophysiology
▶
BP180 expressed in brain tissue at neuromuscular junctions
Neural BP180 isoform may be initial immunization target
Cross-reactivity between neural and skin BP180 may explain neurological disease association
Therapeutic Considerations
Treatment principles and evidence base
▶
Goal of therapy
▶
Achieve blister control, reduce pruritus, prevent secondary infection
Minimize treatment toxicity — a major cause of morbidity and mortality
Sustained remission with gradual treatment withdrawal
Topical clobetasol versus systemic corticosteroids
▶
Whole-body topical clobetasol propionate effective and avoids systemic toxicity
Preferred over systemic steroids in elderly patients with significant comorbidities
Systemic steroids not superior at doses above 0.5 mg per kg per day (Class I evidence)
Doxycycline preference in frail elderly
▶
Williams et al. Lancet 2017 RCT: doxycycline 200 mg per day non-inferior to prednisolone for blister control
Significantly fewer serious adverse events at 12 months with doxycycline
Should be offered as initial therapy in patients at high risk of steroid toxicity
Monitoring anti-BP180 to guide taper
▶
Anti-BP180 ELISA levels correlate with disease activity
Elevated levels at treatment discontinuation predict relapse
Useful to guide decisions about steroid taper speed
Drug-induced BP management
▶
Discontinue suspected offending medication (DPP-4 inhibitor, checkpoint inhibitor)
BP may remit spontaneously after drug withdrawal over weeks to months
Continue BP-specific treatment until disease controlled regardless of drug discontinuation
Patient Discharge Instructions
copy discharge instructions
Copy
Wound care at home
▶
Gentle cleaning of skin with mild soap and water once daily
Apply non-stick dressings to open erosions
If a blister is large and painful, a nurse or doctor can drain it safely — do not tear off the skin over the blister
Apply prescribed topical clobetasol cream to active blistering areas as directed
Medications
▶
Take all prescribed medications as directed
Do not stop corticosteroids or doxycycline without speaking to your doctor first
If you are on prednisone, take it with food to reduce stomach upset
Take calcium and vitamin D supplements daily if prescribed
Skin protection tips
▶
Wear soft, loose-fitting clothing to avoid friction on fragile skin
Avoid scratching — antihistamine medication can help with itching
Keep skin moisturized with fragrance-free emollient
Protect skin from sun exposure if on doxycycline (causes photosensitivity)
Blood sugar monitoring if on prednisone
▶
Check blood sugar as directed if you have diabetes or are at risk
Report high readings to your doctor promptly
Warning signs to return to the emergency department
▶
Sudden worsening with many new blisters appearing daily
Skin becoming red, warm, swollen, with pus or foul odor (infection)
Fever above 38.5 degrees Celsius
Difficulty breathing or chest pain
Confusion, severe agitation, or sudden change in mental status
Inability to eat or drink due to mouth sores
Blood in stool or vomit (possible steroid-related GI bleeding)
Falls or suspected fracture (steroid-related bone fragility)
Follow-up plan
▶
Dermatology appointment within 1 to 2 weeks for biopsy results and treatment review
Return to dermatology every 2 to 4 weeks during active disease
Blood tests as scheduled by your doctor to monitor for medication side effects
Ophthalmology appointment if any eye redness, pain, or vision change
References
Guidelines and key sources
Primary guidelines and society recommendations
▶
European Dermatology Forum guidelines for bullous pemphigoid management
British Association of Dermatologists guidelines for BP
Cochrane systematic review: Singh et al. Interventions for bullous pemphigoid (2023)
Williams HC et al. Doxycycline versus prednisolone for BP — Lancet 2017 RCT
Key diagnostic studies
▶
Grochowska-Rak et al. BP180 and BP230 ELISA meta-analysis — International Journal of Dermatology 2025
▶
Anti-BP180 sensitivity 82%, specificity 94%
Combined ELISA sensitivity reaches 90%
Sardy et al. DIF versus ELISA comparison — JAAD 2013
▶
DIF gold standard: sensitivity 91%, specificity 98%
Meijer et al. Diagnostic strategy for BP variants — JAMA Dermatology 2019
Drug association and special population references
Drug-induced BP evidence
▶
Liu et al. Medication association systematic review and meta-analysis — JAMA Dermatology 2020
▶
DPP-4 inhibitor association: odds ratio approximately 2 to 4
Asdourian et al. Checkpoint inhibitor-associated BP — JAMA Dermatology 2022
Ozeki et al. HLA-DQA1 variants and DPP-4 inhibitor-induced BP — Journal of Investigative Dermatology 2023
Neurological associations and outcomes
▶
Lai YC et al. BP and neurological diseases meta-analysis — JEADV 2016
▶
Dementia OR 4 to 5, Parkinson OR approximately 3, stroke OR 2.7
Shen et al. Mortality risk in BP — JAMA Dermatology 2022
▶
One-year mortality 20 to 40%, 2 to 3 times higher than age-matched controls
Akbarialiabad et al. Bullous Pemphigoid review — Nature Reviews Disease Primers 2025
Coding reference
▶
ICD-10 L12.0 bullous pemphigoid
ICD-10 L12.1 cicatricial pemphigoid
ICD-10 L10.0 pemphigus vulgaris (key differential)
SNOMED CT: bullous pemphigoid disorder concept
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.
← Management Protocols
Home
Management Protocols
Bullous Pemphigoid